Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How J&J Hopes To Disrupt India's Diabetes Care Paradigm

Executive Summary

Sushobhan Dasgupta, managing director of Johnson & Johnson Medical India, discusses how J&J's new go-to-market strategies are playing out, the role of e-commerce for medical devices in India, and how the company is leveraging its capabilities to provide solutions for the whole diabetic care pathway.

You may also be interested in...

Global Device-Makers Want India To Harmonize Standards

US medtech trade group AdvaMed is prodding the Indian government to harmonize what analysts have called “archaic” regulations governing medical devices with international standards, saying the result would be a win-win for both domestic and foreign companies.

INTERVIEW: JnJ Medical India's Chief On The 'Middle India' Push

Johnson &Johnson Medical India is implementing a clutch of new go-to-market approaches and managing director Sushobhan Dasgupta expects these to increase the "depth and breadth" of the US multinational's coverage across the country. J&J is the number one medical devices company in India.

Biocon And Mylan's Fulphila And Insulin Plans On Track

Biocon and Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts